Researchers at the University of Toronto's Temerty Faculty of Medicine have found widespread genetic and protein changes in ...
Researchers at the University of Toronto's Temerty Faculty of Medicine have found widespread genetic and protein changes in ...
The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial ...
This first-in-class ASO replicates the protective effects of naturally occurring CD33 loss-of-function variants, which are associated with increased resilience to neurodegenerative disease, reduced ...
TDP-43 CYTOPE ® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targ ...
Transition Bio and Voyager have teamed to discover and develop new small molecules that target toxic TDP-43 protein clumps in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback